This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Genetic Counseling/ Testing/ Therapy  • Randomized Controlled Trial  • Oncology  • Breast Cancer  • Alert me on articles by topic

Tracy Hampton, PhD

JAMA. 2006;295:2839.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Researchers in the United States and Canada are launching a clinical trial to assess whether an analysis of the activity of certain genes associated with risk of recurrence for women with early-stage breast cancer can be used to determine appropriate treatments for patients (http://www.cancer.gov/clinicaltrials/digestpage/TAILORx).

The Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, sponsored by the National Cancer Institute and coordinated by the Eastern Cooperative Oncology Group, is taking place at 900 sites in the United States and Canada. Researchers will enroll more than 10 000 women recently diagnosed with breast cancer that is estrogen receptor– and/or progesterone receptor–positive, Her2/neu-negative, and that has not spread to the lymph nodes.

Using a diagnostic test called Oncotype DX, investigators will measure the levels of expression of 21 genes and generate a recurrence risk score from 0 to 100 for each patient; the higher the score, the greater . . . [Full Text of this Article]